Online Livestream
West Coast
2nd Medical Affairs & Rare DiseaseWest Coast
Event Overview

The new coronavirus has paralyzed our world, but older diseases remain as dangerous as ever.  Rare disease patient needs have become even more challenging in an age of social distancing and fears of contagion.

To help serve the patients who are under the most risk and are least able to wait for society to reopen, Dynamic Global Events invites you to participate in the 2nd annual Medical Affairs & Rare Disease – West Coast conference – this year held entirely streaming online.  At a time when people are forced to stay apart, this forum helps you unite multi-stakeholder teams across functions, organizations, and therapeutic areas, in order to solve problems and identify rare disease solutions.

Event Sponsors
Conference
New Topics
Featured Speakers
Andy Overmyer
Head of Global Business Operations
Akcea Therapeutics
Angela Ramirez Holmes
Founder/President
Cal Rare
Barbara Wuebbels
Chairman
PROFESSIONAL PATIENT ADVOCATES IN LIFE SCIENCE
Christine Von Raesfeld
Founder / CEO
PEOPLE WITH EMPATHY
Colin Scott
Managing Partner
HIGHLAND AIRS CONSULTING
Dan Donovan
Co-Founder & CEO
rareLife solutions
Harsha K. Rajasimha
Founder and Chairman, INDOUSRARE
Founder Chairman, Indo US Organization for Rare Diseases
Jim Murray
Board Member
PEOPLE WITH EMPATHY
Joan A. Chambers
Senior Director, Marketing & Outreach
The Center for Information & Study on Clinical Research Participation (CISCRP)
Jon Kaskey
Senior Director of Business Partnerships
WITHIN3
Maureen McArthur Hart
Director, Research
Global Genes
May Orfali
Chief Medical Officer
BIOASIS TECHNOLOGIES
Michael Forstner
Senior Vice President and Head of Pharmacoepidemiology and Risk Management
PrimeVigilance
Natalie Douglas
Vice Chairman, GLOBAL GENES
Co-Founder, RAREITI
Oscar Segurado
Chief Medical Officer
ASC Therapeutics
Robert Consalvo
Director of Strategic Commercial Engagement
H1 INSIGHTS
Sarah Krug
Executive Director
CANCER 101
Sheila Bose
President
SB Lifesciences Consulting, Inc
Spandan Chakrabarti
Co-Founder/CFO
PEOPLE WITH EMPATHY
Steven G. Rizk
Senior Director Medical Strategy
Rype Health
Tom Lester
Former Executive Director Program Management
Audentes Therapeutics
Vij Senthilnathan
Board Member
PEOPLE WITH EMPATHY
Wendy White
Chairman, GLOBAL GENES
Co-Founder, RAREITI
Event Schedule

The lack of published literature in rare disease presents an impediment to progressing disease understanding and advancing therapies. Companies developing medical publishing programs need to consider that this is not your everyday medical publications program for a more common disease. As an example, to have a more tangible impact, rare disease publications must be open access and freely available to all stakeholders in rare, including the patient. Breaking down the process we will:

  • Discuss the best methods, timelines, and content requirements for rare disease publications
  • Highlight crucial differences between publishing for rare diseases and more common types
  • Encourage that rare disease clinical trial results are shared with the patient community as a priority and in a legally compliant manner

The patient voice must move to the forefront of clinical trial planning, or else you are at risk of missed endpoints, low enrollment, and wasted time and money.  Dedicated MSL teams can be powerful tools for gathering patient information and, in turn, properly structuring your trials.  With their direct access to the patient voice, they are also vital in educating clinical staff about the disease. 

  • Reorient logistics, consent forms, and follow-ups around the patient voice
  • Rely on medical affairs professionals to verify your assumptions about age spread and disease severity
  • Strengthen advisory board meetings through medical affairs input

Commercial, medical affairs, and medical communications teams must be closely involved from the earliest stages in order to accurately guide sales. This is especially true for rare disease therapeutics for which doctors might see only one patient per month at the most. The entire clinical and medical affairs management cycles for rare disease will have to significantly change in response to the COVID-19 pandemic.

  • Pinpoint the medical affairs and communication partnerships and messaging most essential in new APDS therapeutics
  • Track the key steps in expanding rare disease therapeutics for a new pediatric indication
  • Adapt your methods and messaging to a post-coronavirus world
  • Create trust among stakeholders
  • Envision innovative partnerships focused on solutions, not profits
  • Prioritize transparency, accountability, and conflict resolution in partnerships
  • Grasp how small investments can lead to big returns
  • Create trust among stakeholders
  • Envision innovative partnerships focused on solutions, not profits
  • Prioritize transparency, accountability, and conflict resolution in partnerships
  • Grasp how small investments can lead to big returns
  • Actionable Implications to Achieve Clinical Development, Product Launch Goals,
    Drug Safety and Favorable Outcomes
  • Building High-performing Multi-stakeholder Teams
  • Leading Internal Project Teams Across Functions, Geographies and Therapeutic
    Areas
  • Collaborating Across Organizations -- Science, Business and Non-profits
Register Now

This window is secured by 256 bit encryption on a PCI compliant network. Click here to view this window in its own page.

Subscribe to Conference Updates
Join our e-newsletter list to follow closely all news.
Event Partners
15
Speakers
21
Days
251
Participants
125
Workshops
90
Venue
Contact Us